Work

138P Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial

Year: 2024

Type: article

Abstract: Until recently, neoadjuvant therapy for HCC has been limited by a lack of effective approaches. Prior studies have shown that patients (pts) achieving major pathological response (MPR) with neoadjuvant therapy have improved recurrence-free survival (RFS) in early-stage hepatocellular carcinoma (HCC). This prospective study aimed to explore the efficacy and safety of TACE combined with lenvatinib and tislelizumab in high-risk resectable HCC pts.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100767

Authors: Y. Zhang, J. Wu, F. Han

Institutions: Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170